(Q41947807)

English

Next generation therapies change the landscape in melanoma

scientific article published on April 2011

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

14 October 2017

1 reference

Europe PubMed Central

title

Next generation therapies change the landscape in melanoma (English)

1 reference

stated in

Europe PubMed Central

14 October 2017

1

Keith T Flaherty

1 reference

stated in

Europe PubMed Central

14 October 2017

1 April 2011

1 reference

stated in

Europe PubMed Central

14 October 2017

F1000 medicine reports

1 reference

stated in

Europe PubMed Central

14 October 2017

3

1 reference

stated in

Europe PubMed Central

14 October 2017

8

1 reference

stated in

Europe PubMed Central

14 October 2017

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3096880

retrieved

5 June 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3096880

retrieved

5 June 2018

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3096880

retrieved

5 June 2018

Mutations of the BRAF gene in human cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3096880

retrieved

5 June 2018

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3096880

retrieved

18 August 2018

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3096880

retrieved

18 August 2018

Identifiers

DOI

10.3410/M3-8

1 reference

stated in

Europe PubMed Central

14 October 2017

1 reference

Europe PubMed Central

PMC publication ID

3096880

retrieved

14 October 2017

PubMed publication ID

21654923

1 reference

stated in

Europe PubMed Central

PMC publication ID

3096880

retrieved

14 October 2017

(Q41947807)

Next generation therapies change the landscape in melanoma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)